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Abstract
The process to develop a guideline in a European setting remains a challenge. The ESCMID Fungal Infection Study Group (EFISG) success-
fully achieved this endeavour. After two face-to-face meetings, numerous telephone conferences, and email correspondence, an ESCMID
task force (basically composed of members of the Society’s Fungal Infection Study Group, EFISG) ﬁnalized the ESCMID diagnostic and man-
agement/therapeutic guideline for Candida diseases. By appreciating various patient populations at risk for Candida diseases, four subgroups
were predeﬁned, mainly ICU patients, paediatric, HIV/AIDS and patients with malignancies including haematopoietic stem cell transplanta-
tion. Besides treatment recommendations, the ESCMID guidelines provide guidance for diagnostic procedures. For the guidelines, questions
were formulated to phrase the intention of a given recommendation, for example, outcome. The recommendation was the clinical interven-
tion, which was graded by a score of A–D for the ‘Strength of a recommendation’. The ‘level of evidence’ received a score of I–III. The
author panel was approved by ESCMID, European Organisation for Research and Treatment of Cancer, European Group for Blood and
Marrow Transplantation, European Society of Intensive Care Medicine and the European Confederation of Medical Mycology. The guide-
lines followed the framework of GRADE and Appraisal of Guidelines, Research, and Evaluation. The drafted guideline was presented at
ECCMID 2011 and points of discussion occurring during that meeting were incorporated into the manuscripts. These ESCMID guidelines
for the diagnosis and management of Candida diseases provide guidance for clinicians in their daily decision-making process.
Keywords: Candida, Europe, framework, guideline development, recommendation
Clin Microbiol Infect 2012; 18 (Suppl. 7): 1–8
Corresponding author: A. J. Ullmann, Infectious Diseases, Department of Internal Medicine II, Julius-Maximilians-University, Oberdu¨rrbacher Str. 6,
97080 Wu¨rzburg, Germany
E-mail: andrew.ullmann@uni-wuerzburg.de
Information in this manuscript was presented in part at ECCMID 2011.
*European Society for Clinical Microbiology and Infectious Diseases
Members of the subgroup committee mainly responsible for this manuscript.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ESCMID PUBLICATIONS 10.1111/1469-0691.12037
Introduction
Preparing guidelines in this day and age can be likened to the
quest of the search for the Holy Grail. Numerous guidelines
have been published in a variety of countries and by different
scientiﬁc societies. All have the common goal of proving clini-
cians with best guidance for their daily working environment.
Obviously, there is no single pathway to the truth in the ﬁeld of
medicine because science and the art of medicine are in a con-
stant state of ﬂux, published data might have already become
obsolete and its interpretation might be biased unwittingly.
Nevertheless, it was apparent that certain guidelines for
Europe are missing. Firstly, the majority of guidelines focus on
treatment, usually only one host group at risk, and to a far les-
ser extent only a few focus on diagnostic procedures [1–10].
Moreover, North American guidelines are frequently cited in
the literature, and this demonstrates their clear dominance
[11–15]. Hence, recommendations for diagnostic procedures
provided a clear impetus to our group of microbiologists,
pathologists, haematologists and infectious diseases physicians
(some with dual or more qualiﬁcations). In addition, differ-
ences in epidemiology by geography, age and local factors
needed some attention. Our aim was to provide comprehen-
sive European guidelines focusing on a single fungal disease
entity caused by a single genus, namely Candida species to
allow comprehensive coverage of diagnostics and treatment,
recognizing that not all patient risk are alike. It became obvious
very quickly that a matrix was needed to cover all topics of
interest. This needed to be considered during the guidelines
preparation. The guidelines are published as a supplement to
CMI and aim to provide greater awareness and better insights
into Candida diseases for the clinicians.
It was decided that the guidelines for the diagnosis and
management of Candida diseases is divided into ﬁve separate
parts, each of which can be used as stand-alone recommen-
dations of the ESCMID treatment management guideline for
each risk group of patients and diagnostic procedures.
Methods
Author panel recruitment and organization
The development of any guideline requires certain steps to
ensure the production of an unbiased, independent and high-
quality document. The executive board of EFISG decided to
proceed ﬁrst with a guideline for Candida diseases. The
members of the EFISG group were ﬁrst asked if they wanted
to participate. Participants were chosen on the basis of their
expertise in the ﬁeld of medical mycology and in particular
Candida disease, and further had experience in generating
guidelines (Fig. 1). Contact was made through the ESCMID
Executive Committee with four different European scientiﬁc
societies. European Group for Blood and Marrow Transplan-
tation (EBMT), European Confederation of Medical Mycology
(ECMM), European Organisation for Research and Treat-
ment of Cancer (EORTC) and European Society of Intensive
Care Medicine (ESICM) approved the list of experts and
made additional suggestions for experts. Some of the nomi-
nees are also members of the ESCMID and were included
into the group as panel authors. Experts who were not
FIG. 1.Working modules and experts participating in the development of the guidelines (susceptibility testing is included for the diagnostic pro-
cedures).
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selected were asked to peer review the guideline to ensure
further quality, although the ﬁnal decision for the choice of
peer reviewers rested with the Editor-in-Chief of CMI.
These expert reviewers from the European scientiﬁc socie-
ties are acknowledged in this paper. This is a novel proce-
dure because reviewers are usually not explicitly mentioned
in terms of which papers they have reviewed.
Obviously, to achieve its aim, to provide a European
guideline, the group needed to balance between different
geographical regions of Europe. The list of representatives of
the various European countries is provided in Table 1. For
further proﬁciency, a group coordinator of each subgroup
was nominated to provide and present the results of the dis-
cussion of this subgroup to the plenary sessions. The sub-
groups were set up by EFISG. They searched for relevant
literature (by PubMed). This literature database was made
available to the whole panel on an ftp server of ESCMID.
During 2010–2012, documents and views were shared by
email, teleconferences and face-to-face meetings. Once a ﬁrst
consensus was reached, the preliminary recommendations
were presented to the whole group, that is, the other
authors, and subject to wide discussion, developed further,
and ﬁnalized as a group consensus. Two weekend meetings
took place in 2010 and 2011 to ﬁnalize the guidelines. The
ﬁnished guidelines were presented during a workshop ses-
sion at the ECCMID 2011, and points of discussion occurring
during that meeting were incorporated into the ﬁnal publi-
cized manuscripts. The organization plan used for the guide-
line is provided in Fig. 2.
Intention of the recommendation with deﬁned intervention
During the preparation process, new ideas were incorpo-
rated to provide best clinical guidance. Pragmatic questions
arising in everyday patient care needed to be addressed
appropriately. For this reason, the ‘intention’ for a recom-
mendation was deﬁned beforehand and framed in terms of
‘What does the clinician want?’ and a response was tailored
to address the different aspects of a given Candida disease.
Obviously, the diagnostic and therapeutic intervention that
TABLE 1. List of the representatives associated with the
country
Country Number
(ID)
Number (CM and
diagnostic experts)
Total
number
Austria 0 1 1
Belgium 1 0 1
Denmark 0 1 + 1a 2
France 1 + 1b 0 2
Germany 3c 0 3
Greece 2 0 2
Italy 3 0 3
Netherlands 1 2 3
Spain 0 1 1
Switzerland 2 1d 3
Turkey 1 1d 2
United Kingdom 1 1 2
ID, infectious diseases specialist; CM, clinical microbiologist.
aPathologist.
bHaematologist.
cDual trained in ID and haematology.
dDual trained in ID and CM.
FIG. 2.Organization plan of the guidelines.
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had the greatest impact on survival of the patient was given
the highest priority in terms of a recommendation.
Certain recommendations were originally controversial.
Guidelines are no consensus meeting, but nevertheless, a
majority vote was a necessity to formulate a recommenda-
tion if a major disagreement occurred. Only a few of the dis-
cussions were intense but only had one common goal in
mind—to provide the best option for diagnosis and therapy.
But whatever the decision, it was one we ensured to be the
best for patients.
Every recommendation within the guidelines attempts to
indicate clearly the intention (e.g. improved survival) and to
describe the diagnostic or therapeutic option (intervention).
Therefore, the guidelines follow the principles of the ‘Grades
of Recommendations, Assessment, Development, and Evalua-
tion’ (GRADE) [16]. For every recommendation, the follow-
ing three questions were considered:
1 What do clinicians want (outcomes)? What is their inten-
tion?
2 Which option is better for patients? What intervention is
needed to reach the desired outcome?
3 Review the chosen option whether it is truly better or
not by adequate review of the literature.
These guidelines also adopted the ‘Appraisal of Guidelines,
Research and Evaluation’ (AGREE) items for the development
of guidelines as well [17,18] and basically all domains of AGREE
were addressed:
1 Scope and purpose, for example, clinical questions cov-
ered by the guideline is described.
2 Stakeholder involvement, for example, the patient’s view
and preferences have been sought.
3 Rigours of development, for example, the health-related
beneﬁts, side effects and risks have been considered in
formulating the recommendations.
4 Clarity of presentation, for example, key recommenda-
tions are easily identiﬁable, i.e. tables.
5 Applications, for example, the potential cost-related
implications of applying the recommendations have been
considered.
6 Editorial independence, for example, the guideline is edi-
torially independent from the funding body.
Within the guideline, questions were formulated and
answered according to their clinical importance. Because the
guideline author panel appreciated that not all patients were
alike, various risk groups were deﬁned according to risk and
handled accordingly, that is, patients with HIV/AIDS, those in
the ICU, transplant recipients, haematological malignancies
and cancer and paediatric populations. At all times, the
patient’s view and preferences were kept to the fore. One
good example that caused some heated debates was the rec-
ommendation of not administrating amphotericin B deoxych-
olate to adults. This drug formulation with considerable
toxicity, morbidity and mortality issues, but in regard to
acquisition costs relatively cheap has better alternatives at
least in Europe available albeit at greater costs. The responsi-
bility to ensure good medical help needed to be considered,
and the follow-up costs for the numerous side effects would
make the choice of a less cheaper drug acceptable [19]. The
ethical dilemma although is obvious but on balance, it was
felt that given the facts, the choice of a more expensive for-
mulation was acceptable.
Strength of recommendation
Numerous grading systems of recommendations exist, and it
is imperative that they should be not too complicated to
understand for the user. Hence, we utilized a similar system
as previously employed by the Canadian Task Force of the
Periodic Health Examination and the IDSA [12,20]. This is a
four-category grading system for the ‘strength of a recommen-
dation’. Two extreme ends of the grading system were impor-
tant: (A) ESCMID strongly supports a recommendation for
use and on the other side: (D) ESCMID recommends against
the use. This differentiation was important to clearly deﬁne
treatment management for or against the use of a given inter-
ventions. The grade C is weighted with the evidence available
and could be considered optional (Table 2). The grading of
the ‘strength of a recommendation’ can be compared to traf-
ﬁc lights, with green indicating the recommendation for use
and red the recommendation against use.
The ‘strength of a recommendation’ cannot easily be
applied to diagnostic recommendations. Therefore, an alter-
TABLE 2. Strength of the ESCMID recommendation and
quality of evidence
*
*
T
Un
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native system was adopted for biomarkers (non-cultural
techniques), which included test accuracy, as this plays a
pivotal role in providing an appropriate diagnosis. The
GRADE system was used to grade the ‘strength of a rec-
ommendation’ and ‘quality of evidence’ [21,22]. Therefore,
the system was slightly modiﬁed and is applicable for bio-
markers (non-cultural techniques) only. The term accuracy
of a test was introduced, and a grading system was imple-
mented on those calculated numbers (Table 3). The grading
system used a clear statement, that is, highly recommended,
recommended and not recommended and did not utilize
the alphabet system for treatment. If no published data
were available to support any kind of recommendation, no
recommendation for the test was provided. The equation
for accuracy was the sum of true positive and true negative
tests divided by the sum of all tests performed. The word-
ing for the ‘quality of evidence’ was changed only marginally
to maintain a streamlined recommendation grading system
(Table 3).
Quality of evidence
The ‘strength of a recommendation’ was largely based on
the available studies and publications. Although there were
obvious exceptions, for example, drawing blood cultures for
candidaemia because in this case, no literature was cited. On
the other hand, various publications discussed issues sur-
rounding the selection of appropriate literature [23,24]. This
literature should support the judgement made by the panel.
This guideline is not a classical systematic review of the liter-
ature. It was clearly intended to review the literature on the
impact of the test and alternative management strategies
on the outcome in patients [25]. The panel reviewed
the available evidence and recognized its limitations but
interpretation bias cannot be ruled out entirely. The panel
always kept its focus on the need for an evidence-based
(medicine) justiﬁcation. Despite some limitations in the selec-
tion process, by which means every subgroup was internally
responsible for, all retrieved literature (by PubMed) were
considered. A meta-analysis was not intended and not all
retrieved literature was cited. Nevertheless, we rated the
evidence as the Canadian Task Force on the Periodic Health
Examination and the IDSA [12,20]. One modiﬁcation was
added to the level II of ‘Quality of Evidence’. The panel rec-
ognized that not all questions could be answered by pub-
lished literature but, for example, similar immunological
situations or a substantial abstract from larger international
recognized scientiﬁc meetings could be used as ‘evidence’.
Therefore, especially for academic purposes and to increase
transparency, indices were added to the level II of ‘Quality
of Evidence’ (Table 1).
Discussion and conclusions
These ESCMID guidelines provide a European-wide guideline
for clinical guidance in the diagnosis and treatment of Candida
diseases. The guidelines offer besides diagnostic also treatment
recommendations for various patients’ groups and are
weighted differently according to available literature. The basis
of these guidelines were to follow the framework provided by
GRADE and AGREE [16–18,24–26]. The panel fully acknowl-
edges numerous published guidelines and recognized some
shortcomings that the ESCMID guideline tried to overcome:
Mainly providing an independent European guideline for diag-
nostic procedures and treatment recommendations suitable
for all patients at risk for Candida diseases. Obviously, not all
patient proﬁles are homogeneous, as their risk proﬁle and
response to therapy may differ. Minor changes in the view of
rating systems were implemented into this guideline.
These guideline should also serve as a tool for guiding the
clinical care of patients in Europe. The ESCMID guidelines
consist of text but also includes tables that are easily read-
able. The development of the guidelines was made transpar-
ent, and the panel was also supported by other European
societies as well as a broad panel of experts from various
backgrounds and countries. The guidelines were (peer-)
reviewed by other experts in the ﬁeld of medical mycology
and who were in part suggested by other European societies.
Their pivotal role by peer review in the process of the
guideline development cannot be underestimated and the
entire panel expresses their gratitude by acknowledging their
work at the end of this manuscript.
TABLE 3. System used in these guidelines for grading
quality of evidence about the accuracy of biomarker
detection procedures in the diagnosis of candidiasis
Accuracya
Highly recommended Technique is accurate in >70% of cases (most)
Recommended Technique is accurate in 50–70% of cases
(reasonable number)
Not recommended Technique is accurate in <50% of cases (small number)
No recommendation No data
Quality of evidence accepted
Level I Evidence from at least one properly designed
prospective multicentre cross-sectional or
cohort study
Level II Evidence from
(1) at least one well-designed prospective single-centre
cross-sectional or cohort study or
(2) a properly designed retrospective multicentre
cross-sectional or cohort study or
(3) from case–control studies
Level III Opinions of respected authorities, clinical experience,
descriptive case studies, or reports of expert
committees
aAccuracy was deﬁned as: (Numbers of true positives + true negatives) divided
by (Numbers of true positives + false positives + false negatives + true negatives).
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The development of guidelines comes with a price tag, as
there are inevitably costs incurred by travel and accommoda-
tion. Funding was neither sought nor granted by biomedical
or pharmaceutical companies for the development of these
guidelines. Additionally, biomedical or pharmaceutical compa-
nies were not involved in the development of these guide-
lines neither as observers or discussants. For this reason, we
received a grant of 50 000€ from ESCMID to accomplish this
task. Transparency declarations of the panel are provided to
every guideline. This support by ESCMID guaranteed inde-
pendence including editorial independence.
Challenges remain for the guidelines. Trying to assess Can-
dida epidemiology in Europe remained a challenge because
only a few adequate European publications were available.
The guidelines want to serve as a tool for guidance as for
local (hospital) guidelines, which would require individual
adaptations to meet local needs [27]. Therefore, it remains
important to have European guidelines that can be adapted
to local use.
Costs incurred by diagnostic procedures or treatments are
not considered mainly because of the differences of reim-
bursement systems in Europe. Cost effectiveness calculations
of different treatment modalities have been assessed by others
but are only applicable for the speciﬁc countries (e.g. [28]).
Obviously, more research is needed in the ﬁeld of Candida
diseases particular in epidemiology and the development of
resistance. ‘Strength of a recommendation’ with a grading of
‘C’ highlights our obligation to further work in this area to
arrive at a more adequate or satisfactory answer. The EFISG
is actively developing guidelines in other ﬁelds of medical
mycology (e.g. rare and emerging fungi and aspergillosis) and
will seek cooperation with other scientiﬁc societies sharing
this goal. The current Candida guidelines are planned to be
reviewed in the next 5 years to ensure it remains up to date.
If new and pivotal clinical data become available, then the
planned update will take place earlier.
In summary, these ESCMID guidelines are independent of
any industry funding or support or inﬂuence and were
drafted as an independent recommendation by 25 European
experts from 12 countries. The panel of authors hopes that
these ESCMID guidelines for the diagnosis and management
of Candida diseases will provide adequate guidance for
clinicians in everyday decision-making process, which can be
easily adapted to their clinical practice.
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